Tioma Therapeutics Announces $86 Million Series A Financing
Funding Includes Support of Clinical Development of Anti-CD47 Antibody Program in Multiple Cancer Immunotherapy Trials –
Executive Team Headed by Biotech Industry Veteran John Donovan
St. Louis, MO and Brisbane, CA – August 16, 2016
Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced it has raised $86 million in Series A venture financing. Proceeds from this financing will be used to further develop Tioma’s antibody portfolio, including its lead drug candidate – an anti-CD47 immune checkpoint inhibitor – through advanced proof-of-concept in human clinical trials.